Mycobacterium mageritense pulmonary disease in patient with compromised immune system

Emerging Infectious Diseases

Volumn 17, Issue 3, 2011, Pages 556-558

  Gordon Huth, R ^a   Brown Elliott, Barbara A ^b   Wallace Jr , Richard J ^b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; CORTICOSTEROID; COTRIMOXAZOLE; IMIPENEM; LINEZOLID; PREDNISOLONE;

ADULT; BACKACHE; BACTERIAL PNEUMONIA; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CASE REPORT; COMPUTER ASSISTED DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HEMOPTYSIS; HEPATITIS C; HUMAN; HUMAN TISSUE; HYPOTHYROIDISM; IMMUNOCOMPROMISED PATIENT; LETTER; LUNG BIOPSY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM MAGERITENSE; NEEDLE BIOPSY; NEPHRITIS; NONHUMAN; PNEUMONIA; RHEUMATOID ARTHRITIS; SKIN INFECTION; SLEEP APNEA SYNDROME; SOFT TISSUE INFECTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; VASCULITIS;

ANTITUBERCULAR AGENTS; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; LUNG DISEASES; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS; POLYMERASE CHAIN REACTION;

EID: 79952345223     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1703.101279     Document Type: Letter

References (10)

1. Domenech P, Jimenez MS, Menendez MC, Bull TJ, Samper S, Manrique A, et al. Mycobacterium mageritense sp. nov. Int J Syst Bacteriol. 1997;47:535-40. DOI: 10.1099/00207713-47-2-535
2. Wallace RJ, Brown-Elliott BA, Hall L, Roberts G, Wilson RW, Mann LB, et al. Clinical and laboratory features of Mycobacterium mageritense. J Clin Microbiol. 2002;40:2930-5. DOI: 10.1128/JCM.40.8.2930-2935.2002
3. Appelgren P, Farnebo F, Dotevall L, Studahl M, Jönsson B, Petrini B. Lateonset posttraumatic skin and soft tissue infections caused by rapid-growing mycobacteria in tsunami survivors. Clin Infect Dis. 2008;47:e11-6. DOI: 10.1086/589300
4. Gira AK, Reisenauer AH, Hammock L, Nadiminti U, Macy JT, Reeves A, et al. Furunculosis due to Mycobacterium mageritense associated with footbaths at a nail salon. J Clin Microbiol. 2004;42:1813-7. DOI: 10.1128/JCM.42.4.1813-1817.2004
5. Miki M, Shimizukawa M, Okayama H, Kazumi Y. Case of pulmonary Mycobacterium mageritense infection: the diffi culty of differential diagnosis of granulomatous lung disease. Kekkaku. 2007;82:189-94.
6. Steingrube VA, Gibson JL, Brown BA, Zhang Y, Wilson RW, Rajagopalan M, et al. PCR amplifi cation and restriction endonuclease analysis of a 65-kiloDalton heat shock protein gene sequence for taxonomic separation of rapidly growing mycobacteria [ERRATUM 1995;33:1686]. J Clin Microbiol. 1995;33:149-53.
7. Woods GL, Brown-Elliott BA, Desmond EP, Hall GS, Heifets L, Pfyffer GE, et al. Susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes; approved standard. NCCLS Document M24-A. Wayne (PA): Clinical and Laboratory Standards Institute; 2003.
8. Adékambi T, Colson P, Drancourt M. rpoB-based identifi cation of nonpigmented and late pigmented rapidly growing mycobacteria. J Clin Microbiol. 2003;41:5699-708. DOI: 10.1128/JCM. 41.12.5699-5708.2003
9. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An offi cial ATS/IDSA statement: diagnosis, treatment and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367-416. DOI: 10.1164/rccm.200604-571ST
10. Nash KA, Andini N, Zhang Y, Brown- Elliott BA, Wallace RJ Jr. Intrinsic macrolide resistance in rapidly growing mycobacteria. Antimicrob Agents Chemother. 2006;50:3476-8. DOI: 10.1128/AAC.00402-06